Oruka Therapeutics CEO Lawrence Klein joins us to discuss how his company raised its first round of financing before competing with major players in the inflammation space. We also discuss the latest news in the life sciences, including the end of the Amylyx ALS saga, another use case for GLP-1s, and a hurdle in Verve’s gene editing plans.
Here’s where you ... Show More
Jul 16
409: Predicting biotech clinical trials & a new Alzheimer's drug controversy
On this week’s episode of "The Readout LOUD": The Kalshi prediction markets are coming for biotech, plus the controversy over an experimental Alzheimer’s disease treatment from Biogen. Kalshi, the maker of prediction markets, announced this week that it is expanding into biotech. ... Show More
35m 32s
Jun 2024
Leading with science: A deep dive on biotech
In this episode, David Lebovitz, Global Strategist, Multi-Asset Solutions, is joined by Stephen Squinto, Chief Investment Officer, J.P. Morgan Life Sciences Private Capital, to discuss the alternative investment landscape, the private biotech market and areas of opportunity in 20 ... Show More
17m 43s
Jan 2021
Wall St. Reviving Dream of Bitcoin ETF
Dr. Ken Redcross, Founder of Redcross Concierge, discusses Covid vaccines and communities most at risk. Bloomberg CityLab Reporter Kriston Capps talks about the story “Trump Has One Last Chance to Meddle With Census Numbers.” John Fieldly, CEO at Celsius Holdings, talks about the ... Show More
40m 13s